BRCA2 and neoplasm: Lack of standardization and uniformity, assays that can only measure specific regions of the protein, low throughput, uncertainty as to which functions of BRCA2 are necessary and sufficient for tumor suppression, and discordance between functional assay results with known variants of clinical significance have all likely contributed to the slow adoption.